anti-factor B monoclonal antibody

Anti-factor B monoclonal antibodies are a class of therapeutic biologic agents designed to target and inhibit complement factor B (CFB), a key serine protease in the alternative complement pathway. By binding to factor B (specifically within the third short consensus repeat domain, as characterized by the prototype murine antibody mAb 1379), these antibodies prevent the formation of the active C3bBb convertase complex, thereby selectively blocking alternative pathway activation while leaving the classical and lectin pathways intact. This targeted inhibition is being investigated for the treatment of various complement-mediated inflammatory and autoimmune diseases, including age-related macular degeneration (AMD), asthma, chronic kidney disease (CKD), and paroxysmal nocturnal hemoglobinuria (PNH). Key candidates in this class include TA106 (a humanized Fab fragment derived from mAb 1379, originally developed by Taligen and later acquired by Alexion) and bikaciomab (developed by Novelmed).

Other names

anti-CFB mAbanti-complement factor B monoclonal antibodyanti-factor B antibody